Enbrel, Aimovig and Repatha Patient Assistance: an application guide for practices
Amgen runs patient assistance for Enbrel, Aimovig and Repatha on one application design, issued as a separate form per drug. Each requires prescriber certification, the patient’s consent and signature, and proof of household income. The forms are published in English and Spanish.
Are you a patient? Start with the prescribing practice and use the official manufacturer link above for current program information. AlgoMeds cannot determine eligibility or check an application for you.
Enbrel, Aimovig and Repatha share one application design
These three sit in different clinics (rheumatology and dermatology for Enbrel, neurology for Aimovig, cardiology and primary care for Repatha), but the application a coordinator completes is the same shape in all three.
Each drug has its own form, so an enrollment covers one product for one patient. What transfers between them is process knowledge, not a filing.
For a multi-specialty group this is the unusual case where training staff once genuinely covers three separate service lines.
English and Spanish versions exist for each, so a patient completes their section in the language they actually read.
| Brand | Generic | Used for | How it is given |
|---|---|---|---|
| Enbrel | etanercept | rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis | Self-administered by the patient at home |
| Aimovig | erenumab | preventive treatment of migraine in adults | Self-administered by the patient at home |
| Repatha | evolocumab | lowering LDL cholesterol in adults with cardiovascular disease or familial hypercholesterolemia | Self-administered by the patient at home |
Eligibility factors to verify
Amgen sets the eligibility criteria for the Enbrel, Aimovig and Repatha program and changes them, so the categories below are only the ones programs of this kind generally assess.They are not the criteria for this program, confirm current requirements onAmgen’s official program pagebefore telling a patient anything. We do not publish income thresholds for Enbrel, Aimovig and Repatha here, because a stale number on a marketing page is how a practice ends up telling a patient the wrong thing.
- Insurance status, generally aimed at patients who are uninsured, or insured but unable to access the medication through their coverage.
- Household income against the program’s own published threshold, evidenced by documentation rather than attestation.
- Residency and prescriber licensure requirements set by the program.
- A prescription written for an indication the program covers, certified by the prescribing clinician.
What the application needs
A complete Enbrel, Aimovig and Repatha application is assembled from the four parts below, and because Enbrel, Aimovig and Repatha is self-administered by the patient at home, the part most likely to hold it up is the one this practice controls least. Missing any one of them is what sends a form back rather than forward.
| Part | Who owns it | What it contains |
|---|---|---|
| Prescriber section | Prescribing clinician | Diagnosis, treatment plan, prescribed regimen, prescriber credentials and NPI, and the certification signature. |
| Patient section | Patient or verified legal representative | Demographics, contact and shipping details, insurance status, household information, program consent and the patient’s signature. |
| Income documentation | Patient | Documentary evidence of household income, in whichever forms the program accepts. |
| Program-specific attachments | Practice | Whatever else this specific program requires. Requirements differ between programs and change over time. |
Where practices get stuck
Common workflow challenges for these programs:
- All three are self-injected and ship to the patient, so the patient’s own section is the blocking item on essentially every application.
- Repatha and Aimovig are usually run by teams without a dedicated assistance coordinator, so the work lands on whoever has time that day.
- Both Repatha and Aimovig commonly require documented failure or intolerance of prior therapy, and assembling that history from the chart takes longer than filling the form.
- Enbrel has been on the market long enough that the dominant workload is renewals rather than new applications, and pediatric patients need a guardian signature whose authority has to be recorded rather than assumed.
- Preventive and maintenance therapies feel less urgent to patients than symptomatic ones, so the patient section stalls more often than it does in oncology.
How long an application takes
We do not publish a turnaround figure for Enbrel, Aimovig and Repatha, because Amgen sets it and it moves. What a practice can control is the work before submission. Four factors commonly affect the timeline: how long the patient section takes to return, how many review cycles occur between staff and the prescriber, whether the submission is complete on the first attempt, and the manufacturer review time, which we do not estimate.
How AlgoMeds handles it for Enbrel, Aimovig and Repatha
AlgoMeds opens the correct current Enbrel form, including variant forms that depend on indication, already filled from the patient chart, prescriber profile, insurance on file and prior submitted applications. The patient signs from a single-use, identity-verified link sent by text message, with no account required. This can reduce printing and scanning. Required documents are checked before submission, the application is tracked to a decision, and renewals open ahead of expiry using information from the prior application.
For Enbrel, Aimovig and Repatha, as for every program, AlgoMeds does not determine eligibility, predict approval, or claim to improve the odds of a decision going a particular way. It removes the paperwork between a clinical decision and a submittedEnbrel, Aimovig and Repatha application, nothing more, and nothing that touches the manufacturer’s judgement.See the full coordinator workflow.
Enbrel, Aimovig and Repatha patient assistance: frequently asked questions
Can one application cover a patient on more than one Amgen product?
No. Each drug has its own form and each enrollment covers one product for one patient. The applications look alike because they are built on one design, which is a training benefit rather than a filing shortcut.
Who runs these applications in a practice without a dedicated coordinator?
Usually a shared care-coordination or front-office team. A clear next-action queue is what makes that workable: nobody has to hold the whole process in their head, and the application shows explicitly whose turn it is.
Related program guides
Practices working with this program may also work with these programs. See the full program directory, or therheumatology overview.
Enbrel, Aimovig and Repatha are registered trademarks of Amgen or its affiliates. AlgoMeds is not affiliated with, endorsed by, or sponsored by Amgen. Program details are subject to change. Confirm current requirements with the official program before applying.
This page is general information for medical practices about a manufacturer program. It is not medical advice, not legal advice, and not a determination of eligibility. AlgoMeds does not host or reproduce manufacturer enrollment forms on this website.
Stop retyping the Enbrel form.
Supported fields are filled from practice records, patients can sign from a text message, and staff can track each application from one workflow.